​

Alnylam Pharmaceuticals (ALNY) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ALNY Stock Forecast

Alnylam Pharmaceuticals (ALNY) stock forecast, based on 52 Wall Street analysts, predicts a 12-month average price target of $347.33, with a high of $455.00 and a low of $256.00. This represents a 34.62% increase from the last price of $258.00.

$100 $180 $260 $340 $420 $500 High: $455 Avg: $347.33 Low: $256 Last Closed Price: $258

ALNY Stock Rating

Alnylam Pharmaceuticals stock's rating consensus is Buy, based on 52 Wall Street analysts. The breakdown includes 1 Strong Buy (1.92%), 38 Buy (73.08%), 12 Hold (23.08%), 1 Sell (1.92%), and 0 Strong Sell (0.00%).

Buy
Total 52 12 38 1 Strong Sell Sell Hold Buy Strong Buy

ALNY Price Target Upside V Benchmarks

TypeNameUpside
StockAlnylam Pharmaceuticals34.62%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts51844
Avg Price Target$288.00$368.39$428.64
Last Closing Price$258.00$258.00$258.00
Upside/Downside11.63%42.79%66.14%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Sep, 267156--28
Aug, 268146--28
Jul, 267148--29
Jun, 267158--30
May, 266148--28
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 08, 2026Jefferies$260.00$266.11-2.30%0.78%
Aug 28, 2026Jefferies$230.00$233.50-1.50%-10.85%
Aug 25, 2026Jeffrey WalchBernstein$376.00$236.0159.32%45.74%
Aug 18, 2026BMO Capital$318.00$228.6139.10%23.26%
Aug 14, 2026Derek ArchilaWells Fargo$256.00$227.1212.72%-0.78%
Aug 04, 2026H.C. Wainwright$455.00$215.61111.03%76.36%
Aug 04, 2026Truist Financial$315.00$220.3342.97%22.09%
Aug 03, 2026Eliana MerleBarclays$450.00$205.52118.96%74.42%
Jul 31, 2026Martin AusterRaymond James$420.00$203.31106.58%62.79%
Jul 31, 2026Luca IssiRBC Capital$350.00$203.2972.17%35.66%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 08, 2026JefferiesHoldHoldhold
Sep 02, 2026H.C. WainwrightBuyBuyhold
Aug 31, 2026BernsteinBuyBuyhold
Aug 31, 2026Cowen & Co.BuyBuyhold
Aug 31, 2026BMO CapitalOutperformOutperformhold
Aug 25, 2026BernsteinOutperformOutperformhold
Aug 18, 2026BMO CapitalOutperformOutperforminitialise
Aug 03, 2026Raymond JamesOutperformStrong Buyupgrade
Aug 03, 2026BarclaysOverweightOverweighthold
Jul 31, 2026Raymond JamesOutperformOutperformhold

Financial Forecast

EPS Forecast

$-15 $-8 $-1 $6 $13 $20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-7.20$-9.30$-3.52$-2.18$2.39---
Avg Forecast$-6.44$-8.95$-3.48$-2.10$-1.04$2.91$6.52$12.25
High Forecast$-5.41$-7.68$-2.38$0.75$4.40$9.93$19.04$15.89
Low Forecast$-7.61$-10.93$-4.20$-3.77$-11.85$-1.93$2.05$10.34
Surprise %11.80%3.91%1.15%3.81%-329.81%---

Revenue Forecast

$500M $2B $3B $5B $6B $8B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$844.29M$1.04B$1.83B$2.25B$3.71B---
Avg Forecast$820.81M$1.01B$1.83B$2.24B$2.65B$3.54B$4.54B$5.85B
High Forecast$934.80M$1.19B$1.88B$2.27B$3.06B$3.55B$4.61B$7.19B
Low Forecast$719.95M$902.76M$1.77B$2.20B$2.40B$3.53B$4.47B$5.15B
Surprise %2.86%2.38%0.12%0.35%40.28%---

Net Income Forecast

$-2B $-700M $100M $900M $2B $3B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-852.82M$-1.13B$-440.24M$-278.16M$313.75M---
Avg Forecast$-723.17M$-770.44M$-440.24M$-332.26M$-196.87M$330.06M$942.06M$1.53B
High Forecast$-578.53M$-616.35M$-352.19M$94.21M$549.62M$1.24B$2.38B$1.99B
Low Forecast$-867.80M$-924.53M$-528.29M$-471.06M$-1.48B$-240.59M$255.91M$1.29B
Surprise %17.93%46.82%--16.28%-259.37%---

ALNY Forecast FAQ

Is Alnylam Pharmaceuticals stock a buy?

Alnylam Pharmaceuticals stock has a consensus rating of Buy, based on 52 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 38 Buy, 12 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Alnylam Pharmaceuticals is a favorable investment for most analysts.

What is Alnylam Pharmaceuticals's price target?

Alnylam Pharmaceuticals's price target, set by 52 Wall Street analysts, averages $347.33 over the next 12 months. The price target range spans from $256 at the low end to $455 at the high end, suggesting a potential 34.62% change from the previous closing price of $258.

How does Alnylam Pharmaceuticals stock forecast compare to its benchmarks?

Alnylam Pharmaceuticals's stock forecast shows a 34.62% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Alnylam Pharmaceuticals over the past three months?

  • September 2026: 25.00% Strong Buy, 53.57% Buy, 21.43% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 28.57% Strong Buy, 50.00% Buy, 21.43% Hold, 0% Sell, 0% Strong Sell.
  • July 2026: 24.14% Strong Buy, 48.28% Buy, 27.59% Hold, 0% Sell, 0% Strong Sell.

What is Alnylam Pharmaceuticals’s EPS forecast?

Alnylam Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2026 is $2.91, marking a 21.76% increase from the reported $2.39 in 2025. Estimates for the following years are $6.52 in 2027, and $12.25 in 2028.

What is Alnylam Pharmaceuticals’s revenue forecast?

Alnylam Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2026 is $3.54B, reflecting a -4.60% decrease from the reported $3.71B in 2025. The forecast for 2027 is $4.54B, and $5.85B for 2028.

What is Alnylam Pharmaceuticals’s net income forecast?

Alnylam Pharmaceuticals's net income forecast for the fiscal year ending in December 2026 stands at $330.06M, representing an 5.20% increase from the reported $313.75M in 2025. Projections indicate $942.06M in 2027, and $1.53B in 2028.